Skip to main content

Saphris FDA Approval History

FDA Approved: Yes (First approved August 13, 2009)
Brand name: Saphris
Generic name: asenapine
Dosage form: Sublingual Tablets
Company: Allergan plc
Treatment for: Schizophrenia, Bipolar Disorder

Saphris (asenapine) is an atypical antipsychotic for the treatment of schizophrenia and acute mania or mixed episodes associated with bipolar I disorder.

Development timeline for Saphris

DateArticle
Mar 13, 2015Approval Actavis Receives FDA Approval of Saphris for Pediatric Patients with Bipolar I Disorder
Sep  7, 2010Approval Merck Receives Approval from FDA for Expanded Indications for Atypical Antipsychotic Medication Saphris (asenapine) Sublingual Tablets
Aug 14, 2009Approval Schering-Plough Announces FDA Approval of Saphris (asenapine)
Jul 30, 2009FDA Advisory Committee Votes in Favor of Saphris (asenapine) for Acute Bipolar I Disorder and Acute Schizophrenia
Feb 20, 2009Schering-Plough Submits Response to FDA for Saphris (asenapine) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
Jan 14, 2009FDA Issues Complete Response Letter for Saphris for Acute Treatment of Both Schizophrenia and Bipolar I Disorder
Nov 26, 2007Schering-Plough Announces Asenapine NDA Accepted for Filing by theU.S. FDA

See also

Saphris (asenapine) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer